Vasopressin vs. terlipressinin the treatmentof cardiovascular failure in sepsis

Intensive Care Medicine

Volumn 34, Issue 5, 2008, Pages 821-832

  Lange, Matthias ^a   Ertmer, Christian ^a   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Low dose; Pharmacodynamics; Pharmacokinetics; Septic shock; Vasopressin analogues

Indexed keywords

ADRENALIN; ARGIPRESSIN; CATECHOLAMINE; DESMOPRESSIN; DOPAMINE; INOTROPIC AGENT; LYPRESSIN; NORADRENALIN; PHENYLEPHRINE; TERLIPRESSIN; VASOPRESSIN DERIVATIVE; VASOPRESSIN V1 RECEPTOR; DRUG DERIVATIVE; VASOCONSTRICTOR AGENT;

ARTERIAL PRESSURE; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; CARBON DIOXIDE TENSION; CARDIOGENIC SHOCK; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SUBSTITUTION; ENDOTOXEMIA; ESOPHAGUS VARICES BLEEDING; FLUSHING; GASTRIC HYPOPERFUSION; HEART INDEX; HEART OUTPUT; HEART RATE; HEPATOSPLANCHNIC PERFUSION; HUMAN; HYPOTENSION; ILEAL MICROCIRCULATION; ILEUM DISEASE; INTESTINE PERFUSION; ISCHEMIC SKIN LESION; KIDNEY PERFUSION; LOW DRUG DOSE; LUNG PERFUSION; LUNG VASCULAR RESISTANCE; MONOTHERAPY; NONHUMAN; ORGAN PERFUSION; OXYGEN CONSUMPTION; OXYGEN DELIVERY INDEX; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PORTAL HYPERTENSION; REVIEW; RISK; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN DEFECT; SKIN NECROSIS; STOMACH DISEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; VASOCONSTRICTION; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METHODOLOGY; TREATMENT OUTCOME;

ARGININE VASOPRESSIN; HUMANS; INFUSIONS, INTRAVENOUS; LYSINE VASOPRESSIN; METABOLIC CLEARANCE RATE; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 42449145538     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0946-y     Document Type: Review

References (91)

1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
2. Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595
3. Ince C, Sinaasappel M (1999) Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 27:1369-1377
4. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122-1125
5. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D (2002) Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 30:497-500
6. Papanek PE, Sladek CD, Raff H (1997) Corticosterone inhibition of osmotically stimulated vasopressin from hypothalamic-neurohypophysial explants. Am J Physiol 272:R158-162
7. Day TA, Randle JC, Renaud LP (1985) Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo. Brain Res 358:171-179
8. Zerbe RL, Henry DP, Robertson GL (1983) Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am J Med 74:265-271
9. Giusti-Paiva A, De Castro M, Antunes-Rodrigues J, Carnio EC (2002) Inducible nitric oxide synthase pathway in the central nervous system and vasopressin release during experimental septic shock. Crit Care Med 30:1306-1310
10. Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, Bone HG (2003) Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 31:1502-1508
11. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG (2003) Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301-308
12. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C (2004) Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314-319
13. Scharte M, Meyer J, Van Aken H, Bone HG (2001) Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756-1760
14. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31:2646-2650
15. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P (2004) Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597-604
16. Medel J, Boccara G, Van de Steen E, Bertrand M, Godet G, Coriat P (2001) Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth Analg 93:53-55
17. Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, Ulmer H, Hasibeder WR (2003) Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31:1394-1398
18. Fellahi JL, Benard P, Daccache G, Mourgeon E, Gerard JL (2003) Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin? Ann Fr Anesth Reanim 22:631-634
19. Albanese J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897-1902
20. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR (2001) The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 93:7-13
21. Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic control of vasopressin release. Am J Physiol 236:F321-332
22. Fabian M, Forsling ML, Jones JJ, Pryor JS (1969) The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. J Physiol (Lond) 204:653-668
23. Holmes CL, Landry DW, Granton JT (2003) Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care 7:427-434
24. Umino T, Kusano E, Muto S, Akimoto T, Yanagiba S, Ono S, Amemiya M, Ando Y, Homma S, Ikeda U, Shimada K, Asano Y (1999) AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 276:F433-441
25. Wakatsuki T, Nakaya Y, Inoue I (1992) Vasopressin modulates K (+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 263:H491-496
26. Wenzel V, Lindner KH (2001) Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovasc Res 51:529-541
27. Tan SG, Koay CK, Chan ST (2002) The use of vasopressin to treat catecholamine-resistant hypotension after phaeochromocytoma removal. Anaesth Intensive Care 30:477-480
28. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG (2005) Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol 16:1920-1928
29. Knepper MA, Inoue T (1997) Regulation of aquaporin-2 water channel trafficking by vasopressin. Curr Opin Cell Biol 9:560-564
30. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA, 3rd (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487-493
31. Edwards RM, Trizna W, Kinter LB (1989) Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 256:F274-278
32. Tamaki T, Kiyomoto K, He H, Tomohiro A, Nishiyama A, Aki Y, Kimura S, Abe Y (1996) Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles. Kidney Int 49:722-729
33. Eichinger MR, Walker BR (1994) Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol 267:H2413-2419
34. Evora PR, Pearson PJ, Schaff HV (1993) Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 103:1241-1245
35. Russ RD, Walker BR (1992) Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 262:H743-747
36. Sai Y, Okamura T, Amakata Y, Toda N (1995) Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin. Eur J Pharmacol 282:235-241
37. Evora PR, Pearson PJ, Rodrigues AJ, Viaro F, Schaff HV (2003) Effect of arginine vasopressin on the canine epicardial coronary artery: experiments on V1-receptor-mediated production of nitric oxide. Arq Bras Cardiol 80:483-494
38. Okamura T, Ayajiki K, Fujioka H, Toda N (1999) Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens 17:673-678
39. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN (1988) Hemodynamic and coagulation responses to 1-desamino [8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 318:881-887
40. Phillips PA, Abrahams JM, Kelly JM, Mooser V, Trinder D, Johnston CI (1990) Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands. Endocrinology 126:1478-1484
41. Braunwald E, Wagner HN Jr (1956) The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 35:1412-1418
42. Grollman A, Geiling EMK (1932) The cardiovascular and metabolic reactions of man to the intramuscular injection of posterior pituitary liquid (pituirin), pitressin and pitocin. J Pharmacol Exp Ther 46:447-460
43. Schwartz J, Keil LC, Maselli J, Reid IA (1983) Role of vasopressin in blood pressure regulation during adrenal insufficiency. Endocrinology 112:234-238
44. Schwartz J, Reid IA (1981) Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 109:1778-1780
45. Baker CH, Wilmoth FR (1984) Microvascular responses to E. coli endotoxin with altered adrenergic activity. Circ Shock 12:165-176
46. Bersten AD, Hersch M, Cheung H, Rutledge FS, Sibbald WJ (1992) The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surgery 112:549-561
47. Chernow B, Roth BL (1986) Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock 18:141-155
48. Pleiner J, Heere-Ress E, Langenberger H, Sieder AE, Bayerle-Eder M, Mittermayer F, Fuchsjager-Mayrl G, Bohm J, Jansen B, Wolzt M (2002) Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 22:95-100
49. Baker CH, Sutton ET, Zhou Z, Dietz JR (1990) Microvascular vasopressin effects during endotoxin shock in the rat. Circ Shock 30:81-95
50. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279-1282
51. Williams TD, Da Costa D, Mathias CJ, Bannister R, Lightman SL (1986) Pressor effect of arginine vasopressin in progressive autonomic failure. Clin Sci (Lond) 71:173-178
52. Barrett LK, Singer M, Clapp LH (2007) Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 35:33-40
53. Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, Traber DL, Westphal M (2007) Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 27:281-288
54. Bucher M, Hobbhahn J, Taeger K, Kurtz A (2002) Cytokine-mediated downregulation of vasopressin V (1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 282:R979-984
55. Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576-582
56. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF (2002) Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 30:2548-2552
57. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E (2003) The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 97:1756-1763
58. Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW (2004) Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 32:194-200
59. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313-2319
60. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416-1421
61. Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B (2005) Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659-2666
62. Laszlo FA, Laszlo F Jr, De Wied D (1991) Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43:73-108
63. Pollock WK, MacIntyre DE (1986) Desensitization and antagonism of vasopressin-induced phosphoinositide metabolism and elevation of cytosolic free calcium concentration in human platelets. Biochem J 234:67-73
64. Lachant NA, Smith MR, Xie ZJ, Romani WR (1995) Heterogeneity of the aggregation response of human platelets to arginine vasopressin. Am J Hematol 49:56-66
65. Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699-703
66. Sun Q, Dimopoulos G, Nguyen DN, Tu Z, Nagy N, Hoang AD, Rogiers P, De Backer D, Vincent JL (2003) Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 168:481-486
67. van Haren FM, Rozendaal FW, van der Hoeven JG (2003) The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 124:2256-2260
68. Russell JA Hemodynamic support of sepsis (2007) Vasopressin versus norepinephrine for septic shock. Program and abstracts of Society of Critical Care Medicine Congress February 17-21, 2007, Orlando, Florida
69. Dunser MW, Hasibeder WR, Wenzel V, Schwarz S, Ulmer H, Knotzer H, Pajk W, Friesenecker BE, Mayr AJ (2004) Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 32:1266-1271
70. Pesaturo AB, Jennings HR, Voils SA (2006) Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 40:2170-2177
71. Bernadich C, Bandi JC, Melin P, Bosch J (1998) Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 27:351-356
72. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E (1990) Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 16:307-314
73. Forsling ML, Aziz LA, Miller M, Davies R, Donovan B (1980) Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 85:237-244
74. O'Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine- resistant septic shock. Lancet 359:1209-1210
75. Asfar P, Hauser B, Ivanyi Z, Ehrmann U, Kick J, Albicini M, Vogt J, Wachter U, Bruckner UB, Radermacher P, Bracht H (2005) Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 33:373-380
76. Asfar P, Pierrot M, Veal N, Moal F, Oberti F, Croquet V, Douay O, Gallois Y, Saumet JL, Alquier P, Cales P (2003) Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 31:215-220
77. Ioannou G, Doust J, Rockey DC (2001) Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev:CD002147
78. Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F (2000) Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 20:51-59
79. Ertmer C, Bone HG, Van Aken H, Westphal M (2006) Terlipressin for haemodynamic support in septic shock: less may be more. Resuscitation 70:292-293
80. Westphal M, Traber DL (2005) Low-dose terlipressin for hemodynamic support in sepsis and systemic inflammatory response syndrome: art for (he) art's sake or state of the art? Crit Care Med 33:455-457
81. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858-873
82. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377
83. Asfar P (2003) Terlipressin in chronic hyperdynamic endotoxic shock: is it safe? Intensive Care Med 29:154-155
84. Cooper KE, Kasting NW, Lederis K, Veale WL (1979) Evidence supporting a role for endogenous vasopressin in natural suppression of fever in the sheep. J Physiol (Lond) 295:33-45
85. Cooper KE, Naylor AM, Veale WL (1987) Evidence supporting a role for endogenous vasopressin in fever suppression in the rat. J Physiol (Lond) 387:163-172
86. Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, Bone HG, Van Aken H, Traber DL, Westphal M (2007) Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28:623-629
87. Zeballos G, Lopez-Herce J, Fernandez C, Brandstrup KB, Rodriguez-Nunez A (2006) Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation 68:151-153
88. Morelli A, Ertmer C, Lange M, Westphal M (2007) Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better? Intensive Care Med 33:1669-1670
89. Jolley DH, De Keulenaer BL, Potter A, Stephens DP (2003) Terlipressin infusion in catecholamine-resistant shock. Anaesth Intensive Care 31:560-564
90. Malay MB, Ashton JL, Dahl K, Savage EB, Burchell SA, Ashton RC Jr, Sciacca RR, Oliver JA, Landry DW (2004) Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 32:1327-1331
91. Petersen MB (2006) The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease. Basic Clin Pharmacol Toxicol 99:96-103